Skip to main content
LABT
NASDAQ Life Sciences

Lakewood-Amedex Finalizes Highly Dilutive Series C Offering and Conversions, Doubling Share Count Amid Going Concern Warning

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
9
Price
$0.727
Mkt Cap
$9.981M
52W Low
$0.66
52W High
$9.82
Market data snapshot near publication time

Summary

Lakewood-Amedex has completed a highly dilutive Series C financing and converted all preferred stock and convertible debt, significantly increasing its common share count, while still facing a "going concern" warning.


Key Events

  • Massive Dilution Confirmed

    The company finalized the issuance of shares from a $6.8 million Series C financing and the automatic conversion of all preferred stock and convertible notes, leading to a substantial increase in common shares outstanding.

  • Ongoing Going Concern Warning

    Despite the recent capital infusion, the company continues to express substantial doubt about its ability to fund operations beyond Q4 2026.

  • Deeply Discounted Capital Raise

    The Series C Preferred Stock was issued at a 20% original issue discount, reflecting the challenging terms required to secure financing.

  • Internal Control Weaknesses Identified

    Material weaknesses in internal controls over financial reporting were disclosed, including limited documentation and segregation of duties.


Analysis

This filing confirms the actual issuance of shares from a highly dilutive Series C Convertible Preferred Stock financing and the automatic conversion of all outstanding preferred stock and convertible notes. This event significantly increases the common share count, effectively doubling it. Despite raising $6.8 million, the company continues to carry a "going concern" warning, indicating ongoing financial instability and a need for further capital beyond Q4 2026. The Series C financing was at a deep discount, reflecting the company's challenging financial position.

At the time of this filing, LABT was trading at $0.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10M. The 52-week trading range was $0.66 to $9.82. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LABT - Latest Insights

LABT
May 26, 2026, 4:06 PM EDT
Filing Type: 424B3
Importance Score:
9
LABT
May 22, 2026, 5:01 PM EDT
Source: Wiseek News
Importance Score:
7
LABT
May 22, 2026, 4:55 PM EDT
Filing Type: 10-Q
Importance Score:
9
LABT
May 18, 2026, 9:20 AM EDT
Source: Reuters
Importance Score:
8
LABT
May 14, 2026, 4:18 PM EDT
Filing Type: 424B4
Importance Score:
9
LABT
May 12, 2026, 8:02 AM EDT
Source: PR Newswire
Importance Score:
7
LABT
May 01, 2026, 4:05 PM EDT
Filing Type: S-1
Importance Score:
8
LABT
May 01, 2026, 9:33 AM EDT
Source: Reuters
Importance Score:
8
LABT
Apr 28, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7